(A) B16F0 tumor-bearing mice underwent R1 tumor resection, were
randomized into different treatment groups, and were vaccinated with either
C+I, CpG, or PBS for four weeks. (B) DNA from skin biopsies
(*) in resection areas (RAs) showed a significant reduction in the
percentage of tumor cells after four vaccination rounds with the C+I
vaccine, as assessed by ddPCR. (C) Vaccination post-tumor resection
led to a reduction of Th17 cells
(CD4+CD62L+TCR-b+(IL-2/IL-17A);
CD4+CD62L+CD44+TCR-b+(IL-17A))
and an increased presence of TNF-α expressing myeloid cells
(CD11b+CD44+GR1hi(TNF-a))
and IL-4 expressing
CD19+CD62L+CD44+
B-cells (n=8 PBS, n=10 CpG,
n=10 C+I, mean±s.e.m., ANOVA with
Tukey’s multiple comparison test, *p<0.05).
SQ: subcutaneous injection.